State-owned National Development Co. (NDC) and Glovax Lifescience Corp., a partnership between South Korea’s EuBiologics Corp. and Filipino firm Glovax Lifescience, are co-investing for the establishment of the country’s first vaccine manufacturing project, estimated to cost between P6 billion to P7.5 billion.
On hand to witness this historic event were various key participants and stakeholders in the project; including NDC’s General Manager Anton Mauricio and his entire management team and former NDC General Manager Ditas Rebueno as the investment plan started under her term.
In his speech, General Manager Antonilo Mauricio personally narrated how his bout with the Covid virus during the pandemic illustrated how the country could have been better served with its own vaccine manufacturing facility, and how the NDC remains committed to supporting Glovax Lifescience Corp. as a minority co-investor.
Mauricio cited the Glovax Vaccine Plant in Taysan, Batangas as emblematic of what NDC pursues in its investment objectives as NDC envisions a world-class plant in the country and how the vaccine manufacturing plant would help contribute to the country’s national health security and reduce dependence on vaccine importation. (Bernie Cahiles-Magkilat)